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Background: Add-on prolonged-release melatonin (PRM) in antihypertensive therapy has 
been shown to ameliorate nocturnal hypertension. Hypertension is a major comorbidity among 
insomnia patients. The efficacy and safety of PRM for primary insomnia in patients aged 
55 years and older who are treated with antihypertensive drugs were evaluated.
Methods: Post hoc analysis of pooled antihypertensive drug-treated subpopulations from four 
randomized, double-blind trials of PRM and placebo for 3 weeks (N[PRM] = 195; 
N[placebo] = 197) or 28 weeks (N[PRM] = 157; N[placebo] = 40). Efficacy measurements 
included Leeds Sleep Evaluation Questionnaire scores of quality of sleep and alertness and 
behavioral integrity the following morning after 3 weeks, and sleep latency (daily sleep diary) 
and Clinical Global Impression of Improvement (CGI-I) after 6 months of treatment. Safety 
measures included antihypertensive drug-treated subpopulations from these four and three 
additional single-blind and open-label PRM studies of up to 1 year (N[PRM] = 650; 
N[placebo] = 632).
Results: Quality of sleep and behavior following wakening improved significantly with PRM 
compared with placebo (P , 0.0001 and P , 0.0008, respectively). Sleep latency (P = 0.02) 
and CGI-I (P = 0.0003) also improved significantly. No differences were observed between 
PRM and placebo groups in vital signs, including daytime blood pressure at baseline and treat-
ment phases. The rate of adverse events normalized per 100 patient-weeks was lower for PRM 
(3.66) than for placebo (8.53).
Conclusions: The findings demonstrate substantive and sustained efficacy of PRM in primary 
insomnia patients treated with antihypertensive drugs. PRM appears to be safe for insomnia in 
patients with cardiovascular comorbidity.
Keywords: prolonged-release melatonin, hypertension, nocturnal blood pressure, insomnia, 
cardiovascular disease, sleep quality
Introduction
Insomnia, defined as difficulties initiating or maintaining sleep or nonrestorative sleep 
associated with significant daytime distress (Diagnostic and Statistical Manual of 
Mental Disorders, 4th ed [DSM-IV]), occurs in about 30% of subjects aged 55 years 
and older.1–6 One of the major health issues found in the 55+ years population is 
hypertension.7,8 The prevalence of hypertension is significantly higher among insomnia 
patients (∼44%) as compared with good sleepers (∼19%), suggesting a cross-talk 
between sleep and blood pressure (BP) control.9 In particular, higher systolic BP and 
lower day-to-night systolic BP dipping were reported in normotensive insomniacs as 
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compared with in normotensive good sleepers.10 Furthermore, 
short sleep duration and insomnia were found to be risk fac-
tors for hypertension, as assessed in middle-aged subjects 
and depressed patients.11,12 In the elderly, it was shown that 
impaired sleep architecture as expressed by decreased slow-
wave sleep increases the risk of developing hypertension.13 
The blunted nocturnal BP dip and the resulting nocturnal 
hypertension have severe consequences and are considered 
major risk factors for cardiovascular events.14 Accordingly, 
a recent Dutch population-based cohort study of 20,432 men 
and women aged 20–65 years revealed that short sleepers 
with poor sleep quality had a 63% higher risk of cardiovas-
cular disease (CVD) and a 79% higher risk of coronary heart 
disease compared with normal sleepers with good quality 
sleep.15 Add-on controlled-release and prolonged-release 
melatonin (PRM) preparations for antihypertensive therapy 
have been shown to ameliorate nocturnal hypertension.16 It 
is therefore important to find out whether such preparations 
would effectively treat insomnia in patients who have car-
diovascular comorbidity.
PRM (Circadin®, Rad Neurim Pharmaceuticals EEC Ltd, 
Reading, UK) is a new drug licensed to treat primary insom-
nia in patients aged 55 years and older. It is designed to mimic 
the release pattern of endogenous melatonin, a hormone that 
regulates sleep and circadian rhythms.17 There is an age-re-
lated decline in the robustness of the biological clock and 
melatonin production, thus depriving the brain of an impor-
tant sleep regulator.18–21 In patients aged 55 years and over 
who suffer from poor sleep quality, melatonin production is 
even lower than in healthy elderly without such a complaint.22,23 
PRM (2 mg) has been shown to be effective in improving the 
patient-reported quality of sleep and morning alertness as 
well as sleep latency in insomnia patients.24–28 It was thus 
pertinent to check whether add-on of PRM improves quality 
of sleep, sleep latency, and next-day alertness in patients aged 
55 and older with primary insomnia who are treated with 
antihypertensive drugs. The safety of PRM in this population 
was also of interest because of potential drug interactions 
with medications used for the treatment of CVD, including 
hypertension.
The efficacy and safety of treatment with PRM and pla-
cebo were thus compared in a subpopulation from PRM 
clinical trials of the insomnia patients aged 55 years and older 
treated with antihypertensive drugs when entering the studies. 
A post hoc, pooled analysis of four randomized, double-blind 
trials (short-term 3-week studies and a long-term 6-month 
study)24–28 with similar designs compared the efficacy of PRM 
and placebo (3 weeks up to 6 months) in the treatment of 
primary insomnia in this subpopulation. Safety measures 
included vital signs as well as the frequencies of adverse 
events (AEs) along with general safety measures in all 
patients with insomnia from these four and three additional 
single-blind and open-label PRM trials that had a recorded 
history of any cardiovascular abnormalities when entering 
the trials.
Methods
Studies: efficacy analysis
Data from four clinical trials conducted between 1998 and 
2008 were used for the efficacy analysis.24–28 These trials 
shared the same basic design, which included 1–2 weeks of 
a single-blind placebo run-in period followed by a 3-week 
randomized, double-blind treatment period. Patients were 
instructed to take either PRM 2 mg (Circadin®) or a placebo 
tablet daily 2 hours before bedtime. Efficacy parameters were 
measured at the beginning (baseline) and at the end of the 
3-week double-blind period. In one of these studies,27 the 
double-blind treatment was then continued for 6 months, 
wherein patients randomized to PRM continued and those 
randomized to placebo were re-randomized to PRM and 
placebo for 6 months (Figure 1). Another study24 included a 
6- to 12-month open-label extension phase of PRM 2 mg 
treatment, which contributed safety data.
Studies: safety analysis
Safety analysis was performed for all patients included in 
the efficacy analysis. For the sake of completeness of the 
data, the analysis included also all patients with insomnia 
and any recorded CVD aged 55 years and older from two 
additional single-blind safety trials23,26 and a long-term open-
label extension phase of one study.24 In these trials, patients 
aged 18–80 years participated, and PRM doses used were 
0.1 mg, 1 mg, 2 mg, and 5 mg daily for 3–52 weeks. 
  Altogether, the number of patients with any recorded CVD 
included in the safety analysis was N[PRM] = 650 and 
N[placebo] = 632.
All study protocols were approved by local ethics com-
mittees and complied with Good Clinical Practice standards 
stated in the Declaration of Helsinki 1975.
Subjects
In the included double-blind PRM trials, eligible patients 
were men and women aged 55–80 years suffering from 
primary insomnia according to DSM-IV criteria and for 
whom this was the main consultation complaint. A four-step 
process was used for screening out patients with secondary 
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sleep disorders, including depression and other sleep 
  disorders. First, a Sleep History Questionnaire (SHQ) was 
used. This SHQ, which was adopted from the Management 
of Insomnia Guidelines for Clinical Practice of the World 
Psychiatric Association, characterizes the primary sleep 
complaint and also helps in differentiating primary insomnia 
from secondary insomnia due to medical and psychiatric 
disorders (including depression and anxiety) and specific 
insomnia disorders like circadian rhythm disorders, 
m  ovement disorders, parasomnias, and breathing-related 
sleep disorders. Second, the SHQ was performed at the 
screening visit by a qualified clinician. Third, in order to rule 
out psychiatric disorders, including depression anxiety and 
dementia, the patients went through a detailed psychological 
assessment that included the Raskin Depression Scale, Covi 
Anxiety Scale, and Mini-mental State Examination at Visit 1. 
Finally, patients who were using psychotropic treatments 
(neuroleptics, antiepileptics, barbiturates, antidepressants, 
anxiolytics, and lithium) in the previous 3 months before the 
study were excluded. A positive drug screen on Visit 2 for 
Patients with baseline data (n = 401)
Patients with baseline data (n = 197)
Eligible for analysis (n = 412)
Incomplete data (n = 11)
Allocated to PRM (n = 200)
Allocated to placebo (n = 40)
Allocated to placebo (n = 201)
Allocated to PRM (n = 157)
Completed 3 weeks (n = 197)
Discontinued intervention (n = 4)
        – Adverse event 2
        – Non compliance 1
        – Consent withdrawn 1
Completed 3 weeks (n = 195)
Discontinued intervention (n = 5)
        – Adverse event 1
        – Ineligible to continue 2
        – Unwilling to continue 2
Completed 3 weeks (n = 36)
Discontinued intervention (n = 4)
        – Adverse event 1
        – Ineligible to continue 1
        – Unwilling to continue 2
Completed 3 weeks (n = 138)
Discontinued intervention (n = 19)
        – Adverse event 7
        – Noncompliance 1
        – Investigator withdrawn 1
        – Unwilling to continue 10
Allocation
Allocation
End of 3-week
period
End of 
6-month period
Eligible for analysis of long-term
extension period (n = 200)
Incomplete data (n = 3)
Figure 1 Overall patient disposition in efficacy analysis. Analysis of the short-term period included eligible patients who completed 3 weeks of double-blind treatment with 
prolonged-release melatonin (PRM) or placebo. Analysis of the long-term period included patients of one study27 re-randomized to PRM and placebo for 26 weeks of treatment.
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benzodiazepines, barbiturates, sedating antihistamines, 
hydroxyzine, doxylamine, zaleplon, zopiclone, or zolpidem 
led to immediate exclusion. In addition, patients had to report 
any concomitant medication, and any patient who reported 
using any psychotropic treatment as detailed was not random-
ized in the study. For the purpose of the current analysis, 
patients were selected if their medical history included 
hypertension and if they received antihypertensive medica-
tion before and during the study.
Efficacy measures
The primary efficacy measures in the short-term (3 weeks) 
studies were the improvements in quality of sleep and morn-
ing alertness as assessed by the Leeds Sleep Evaluation 
Questionnaire (LSEQ). The LSEQ is a widely used standard-
ized instrument for the measurement of sleep difficulties in 
clinical settings.29 It is a retrospective instrument by which 
the patients are asked to contrast aspects of their current sleep 
with those at the time before they joined the study. The LSEQ 
comprises ten individual visual analog scales (100 millimeters) 
shown by factor analysis to assess four discrete domains that 
are used independently to assess the following aspects of 
sleep and daytime behavior: getting to sleep, quality of sleep 
(QOS), awakening from sleep, and behavior following wak-
ening (BFW).30,31 The QOS domain is the mean of Questions 
4 and 5, which relate to the question “How would you 
describe the quality of your sleep compared with normal 
sleep?”. Alertness and behavioral integrity the following 
morning (BFW) is the mean of Questions 8, 9, and 10 (“How 
do you feel when you wake up?, How do you feel now?, How 
would you describe your balance and coordination upon 
awakening?”). The LSEQ is used in a repetitive manner, 
yielding a series of measurements, and the difference between 
current and preceding measurements is used in drug efficacy 
evaluations.29 Patients were asked to fill in the LSEQ 2 hours 
after awakening and to evaluate their quality of sleep and 
morning behaviors as compared with the respective values 
before starting run-in. Patients in all four studies completed 
the LSEQ during the last 3 days of the run-in period (baseline 
measurement) and the last 3 days of the 3-week treatment 
period. The changes in each parameter averaged over three 
consecutive days from run-in placebo (baseline) to end of 
the 3-week treatment were calculated for each patient. In the 
long-term study,27 patients completed a daily sleep diary. The 
main efficacy parameter in this study was the patient-reported 
time taken to fall asleep (sleep latency) measured over the 
last 7 days of baseline and treatment period. The global 
improvement in patients’ health status, assessed in each patient 
using Clinical Global Impression of   Improvement (CGI-I),32 
is also presented as a measure of overall benefit to the 
patients. The CGI rating scales are commonly used measures 
of symptom severity, treatment response, and efficacy of 
treatments. This is a validated subjective scale that requires 
the user of the scale to compare the subjects with typical 
patients in the clinician experience. The CGI-I is a seven-point 
scale that requires the clinician to assess how much the 
patient’s illness has improved or worsened relative to a base-
line state at the beginning of the intervention and can be rated 
as 1, very much improved; 2, much improved; 3, minimally 
improved; 4, no change; 5, minimally worse; 6, much worse; 
or 7, very much worse.
Safety
Vital signs, including BP (daytime), were measured at each 
visit as a measure of safety and tolerability. AE incidences 
were pooled, including those in patients for whom cardio-
vascular abnormality was recorded in either their medical 
history or the pretreatment physical examination. In an 
attempt to adjust for differences in duration of exposure 
between short- and long-term treatment periods with PRM 
and placebo, the incidences of AEs normalized for the expo-
sure period (per 100 patient-weeks) were also presented.
Statistical analysis
Analyzed variables were presented in summary tables provid-
ing sample size (N), arithmetic mean, standard deviation, and 
minimum and maximum values. An analysis of covariance 
(ANCOVA) model was applied for testing the significance 
of the differences in efficacy measures between the study 
groups adjusted to baseline value and study. χ2 analysis was 
applied for comparing responder rates assessed by the CGI-I 
score between PRM and placebo groups after 6 months of 
treatment. A responder was defined as a patient who scored 1 
(very much improved) or 2 (improved) in CGI-I at the end of 
the 6-month period. Student’s t-test analysis was applied for 
comparing mean group BP (daytime measurement) at baseline 
and after 3 weeks (for all studies) and 6 months (long-
term study).27,28 Effect size was calculated using Cohen’s d.33 
All tests applied were two-tailed, and a P value #5% was 
considered statistically significant. The data were analyzed 
using SAS® (v 9.1; SAS Institute, Cary, NC).
Results
Efficacy
A total of 412 primary insomnia patients (139 men, 273 
women) who had a medical history of hypertension and 
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concomitant therapy records of hypertension (with or 
without other CVD) were included in the PRM trials. Of 
these, 392 completed the 3-week randomized, double-blind 
treatment period, had valid efficacy data, and were 
included in the analysis (see Figure 1 for full details). All 
of these subjects were concomitantly treated with at least 
one antihypertensive drug (26% with ß-blockers, 53% 
with renin-angiotensin system inhibitors, and 33% with 
calcium channel blockers). The majority of patients 
received two or more kinds of antihypertensive medica-
tions concomitantly, and the minority (19.6%; N = 77) 
received one kind of antihypertensive medication (3.8% 
ß-blockers, 6.1% angiotensin-converting enzyme inhibi-
tors, 3.6% calcium channel inhibitors, and 6.1% other 
kind of medication such as diuretics and serum lipid-
reducing agents).
The effects of PRM (Circadin®, 2 mg) and placebo 
treatment on sleep quality in this population are presented 
in Table 1. The patients have demonstrated a statistically 
significant improvement in QOS with PRM for 3 weeks 
compared with placebo with a mean improvement 
(decrease) from baseline of 9.2 with PRM versus 
3.7 millimeters with placebo (df = 1; F = 16.67; 
P , 0.0001, ANCOVA adjusted to baseline and study). 
The effect of PRM on BFW the following morning is 
presented in Table 2. A statistically significant improve-
ment in BFW with PRM for 3 weeks compared with 
placebo was found, with a mean improvement (decrease) 
from baseline of 7.2 with PRM versus 3.0 millimeters with 
placebo (df = 1; F = 11.9; P , 0.0008, ANCOVA adjusted 
to baseline and study). The corresponding effect size 
(Cohen’s d) was 0.35 for QOS and 0.3 for BFW.
By the end of the 6-month treatment period, the mean 
improvement (decrease) in patients’ evaluated sleep latency 
(reported in the daily sleep diary) was significantly higher 
with PRM (25.89 minutes) than with placebo (7.54 minutes) 
(df = 1; F = 8.74; P = 0.02, ANCOVA) (Table 3). The 
Cohen’s d effect size was 0.39.
Following the 6-month treatment period, 38.9% of the 
patients improved or very much improved in CGI-I as com-
pared with 12% of placebo-treated patients (χ2 = 7.87; 
P = 0.0003).
The association between the concomitant antihyperten-
sive therapy and response to PRM could not be obtained, 
because only ∼20% of the patients included in the analysis 
had been treated with one kind of antihypertensive medica-
tion, and the vast majority (∼80%) of the patients had been 
treated with more than one antihypertensive medica-
tion concomitantly. For about 26% of patients the antihy-
pertensive medications included ß-blockers. No significant 
differences in response were found between patients 
who, among other drugs, received ß-blockers and those who 
did not.
Safety
No significant differences were found in vital signs, 
including BP, between insomnia patients with antihyper-
tensive drugs receiving PRM or placebo in the efficacy 
population at the baseline visit or after 3-week or 6-month 
PRM treatment (Table 4).
Table 1 Improvement in quality of sleep with PRM compared to placebo (3 weeks)
PRM Placebo
N Mean (millimeters) SD N Mean (millimeters) SD
Baseline 200 52.8 14.5 201 53.4 13.9
3 weeks 195 43.9 14.4 197 49.5 14.5
Mean change from baseline 195 -9.2 16.2 197 -3.7 15.0
Significance PRM vs placebo P , 0.0001
Abbreviations: PRM, prolonged-release melatonin; SD, standard deviation.
Table 2 Efficacy of PRM vs placebo: improvement in morning alertness compared to placebo (3 weeks)
PRM Placebo
N Mean (millimeters) SD N Mean (millimeters) SD
Baseline 199 49.9 14.5 201 50.9 14.7
3 weeks 195 43.1 15.1 197 47.7 14.3
Mean change from baseline 194 -7.2 15.1 197 -3.0 12.5
Significance PRM vs placebo P , 0.008
Abbreviations: PRM, prolonged-release melatonin; SD, standard deviation.
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For the AE analysis, altogether, 650 PRM-treated patients 
and 632 placebo-treated patients with a recorded history of 
cardiovascular abnormalities or who were diagnosed prior 
to the trials were evaluated. No changes in vital signs were 
observed with PRM in this population. The overall rate of 
AEs recorded in these patients was somewhat higher in PRM 
(41.8%) versus placebo-treated patients (36.6%). However, 
when normalized per exposure time, the AE occurrences per 
100 patient-weeks was much lower for PRM (3.66) than for 
placebo (8.53). As can be seen in Table 5, the main 
contributors to the differences in AEs with PRM versus 
placebo per 100 patient-weeks are gastrointestinal 
(0.86 vs 1.84), infections and infestations (0.95 vs 1.36), 
nervous system disorders (0.95 vs 2.66), and psychiatric 
disorders (0.41 vs 1.81), all of which are lower with PRM 
than with placebo treatment. Cardiovascular-related AEs were 
rare (,0.3%), with no significant differences between PRM 
and placebo.
Discussion
The results of the current post hoc analysis using the primary 
efficacy endpoints from the individual studies demonstrate 
that in insomnia patients aged 55 years and older with a his-
tory of hypertension and concomitant treatment with 
  antihypertensive drugs, treatment with PRM improves sleep 
quality and next-day alertness significantly more than 
  placebo. Long-term benefit to these patients was also dem-
onstrated by the significantly greater improvements in sleep 
latency treated for 6 months with PRM compared with 
  placebo. The effect size of ∼0.35 obtained with PRM in these 
three sleep variables in comparison with placebo is consid-
ered medium,33 quite comparable with those of hypnotics,34 
and well within the range of effect sizes found with central 
nervous system drugs,35,36 and is therefore of clear clinical 
relevance. Benefit to patients is confirmed by the higher 
percentage of patients who improved or very much improved 
in CGI-I with PRM compared with placebo following 
6 months of treatment. The safety profile of PRM in this 
population is benign compared with placebo. This implies 
that add-on PRM therapy does not present significant risks 
of detrimental drug interactions with the main drugs used to 
treat CVD, including hypertension, for long-term periods.
Because hypertension is linked to insomnia,9 the efficacy 
of PRM in improving sleep and morning alertness in patients 
with insomnia may in part be due to lowering nocturnal BP. 
Notably, in a 24-hour ambulatory BP monitoring study, 
53% of the patients treated with antihypertensive drugs 
demonstrated nondipping/nocturnal hypertension despite 
Table 3 Efficacy of prolonged-release melatonin (PRM) compared with placebo (6 months): improvement in sleep latency (daily 
sleep diary)
Daily sleep diary score PRM Placebo
N Mean length of  
time (minutes)
SD N Mean length of  
time (minutes)
SD
Baseline 134   73.6 5.6 39 73.5 4.3
6 months 121   51.0 3.6 36 65.2 4.4
Mean change from baseline 121 -23.3 2.9 36 -7.5 3.6
Significance for PRM vs placebo P = 0.02
Abbreviations: PRM, prolonged-release melatonin; SD, standard deviation.
Table 4 Blood pressure measurement taken at baseline, 3 weeks, and 6 months as part of safety vital signs collection
Baseline 3 weeks
PRM (n = 131) Placebo (n = 185) PRM (n = 131) Placebo (n = 185)
Systolic Diastolic Systolic Diastolic Systolic Diastolic Systolic Diastolic
Short term
Mean 132.27 76.83 132.24 76.94 131.96 75.81 130.53 75.51
SD   15.91   8.09   14.4   8.56   13.76   7.68   13.53   8.86
Baseline 6 months
  PRM (n = 125) Placebo (n = 25) PRM (n = 125) Placebo (n = 25)
Systolic Diastolic Systolic Diastolic Systolic Diastolic Systolic Diastolic
Long term
Mean 131.25 76.36 125.69 75.23 128.73 73.72 124.13 75.29
SD   16.3   8.7   12.5   8.2   15.8   7.2   10.3   6.0
Abbreviations: PRM, prolonged-release melatonin; SD, standard deviation.
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pharmacotherapy,37 suggesting that antihypertensive treat-
ment does not restore proper circadian rhythms in BP. PRM 
and other controlled-release melatonin formulations (2–3 mg) 
but not immediate-release formulations have been consis-
tently shown to reduce nocturnal BP.16 The other way around 
is less likely, as improvement in sleep alone, such as with 
benzodiazepine/benzodiazepine-like hypnotics, does not 
improve nocturnal hypertension. In fact, zolpidem, the most 
commonly used hypnotic drug, does not lessen, and can even 
increase, nocturnal BP.38,39
A limitation in our study is that no measurements of 
nocturnal BP were taken in the clinical trials included in the 
combined analysis. However, it is important to note that BP 
(daytime) measured in all of the studies as part of general 
safety vital sign assessments was not impaired with PRM 
compared with placebo, suggesting that PRM did not reduce 
the efficacy of the antihypertensive therapy. These data agree 
well with studies on the effects of PRM and controlled-
release melatonin preparations in patients with nocturnal 
hypertension, all of which showed a decrease in BP during 
the night and no change during the day (reviewed by 
Grossman et al).16 Therefore, it is possible that the improve-
ment in nocturnal hypertension augments the soporific effects 
of PRM in insomnia patients who are treated with antihy-
pertensive drugs. Both effects may nevertheless be related 
to the effects of PRM on the biological clock regulating the 
day–night cycles in sleep and wakefulness and BP. An 
ambulatory BP monitoring study examining the effect of 
PRM on insomnia patients with hypertension to shed more 
light on the inter-relation between insomnia and nocturnal 
BP is thus warranted.
All of the patients in the hypertensive insomnia subpopula-
tion in our studies were treated with antihypertensive medica-
tions (mostly ß-blockers, calcium channel blockers, and 
angiotensin-converting enzyme inhibitors). Nevertheless, 
because most of the patients received two and sometimes three 
or four antihypertensive medications, we could not determine 
whether the improvement in sleep and daytime parameters 
with PRM was specifically associated with the concomitant 
use of a particular antihypertensive drug. Specifically, 
ß-blockers are known to reduce endogenous melatonin 
secretion40 and induce insomnia.41 We did not observe major 
differences in response to PRM between patients treated with 
ß-blockers or not treated with ß-blockers. This is perhaps 
because melatonin is low in patients with hypertension or 
coronary heart disease,42–45 or because some of the ß-blockers 
used do not affect melatonin.46,47 Altogether, PRM appears to 
be effective and safe for the treatment of insomnia in patients 
with insomnia and cardiovascular comorbidity, including 
hypertension, and may therefore serve as the first choice of 
hypnotics for patients with hypertension.
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